1
|
Gravett RM, Marrazzo J. What’s Old Is New: the Evolution of Lymphogranuloma Venereum Proctitis in Persons Living with HIV. Curr Infect Dis Rep 2022. [DOI: 10.1007/s11908-022-00781-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
2
|
Woodson EN, Katz SS, Mosley SS, Danavall DC, Bowden KE, Chi KH, Raphael BH. Use of real-time PCR as an alternative to conventional genotyping methods for the laboratory detection of lymphogranuloma venereum (LGV). Diagn Microbiol Infect Dis 2021; 101:115532. [PMID: 34571353 DOI: 10.1016/j.diagmicrobio.2021.115532] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 08/20/2021] [Accepted: 08/21/2021] [Indexed: 11/26/2022]
Abstract
Lymphogranuloma venereum (LGV) can be differentiated from non-LGV chlamydial infection using Sanger sequencing or molecular assays, including those that are commercially-available internationally. Here, we describe the performance of a rapid real-time PCR (RT-PCR)-based strategy in differentiating Chlamydia trachomatis infections associated with LGV or non-LGV serovars. One hundred three rectal swabs, previously genotyped using Sanger sequencing of the ompA gene as a reference method, were tested in the RT-PCR assays. All non-LGV specimens were correctly identified, but the RT-PCR failed to detect 1 LGV specimen, resulting in a sensitivity of 87.5% for the non-LGV/LGV RT-PCR assay. Additional performance characteristics (e.g., specificity, accuracy, and reproducibility) were all between 93% and 100% with a limit of detection ≤100 copies/reaction. Thus, this rapid RT-PCR method for LGV detection in clinical specimens is comparable to the reference method.
Collapse
Affiliation(s)
- Evonne N Woodson
- Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of STD Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
| | - Samantha S Katz
- Division of STD Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Sheree S Mosley
- Division of STD Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Damien C Danavall
- Division of STD Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Katherine E Bowden
- Division of STD Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Kai-Hua Chi
- Division of STD Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Brian H Raphael
- Division of STD Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|